› 2vco

X-ray diffraction
2.1Å resolution

Crystal structure of the fimbrial adhesin FimH in complex with its high-mannose epitope

Released:
DOI: 10.2210/pdb2vco/pdb
PDB entry 2vco coloured by chain, front view.
PDB entry 2vco coloured by chain, side view.
PDB entry 2vco coloured by chain, top view.
Source organism: Escherichia coli
Primary publication:
Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.
Wellens A, Garofalo C, Nguyen H, Van Gerven N, Slättegård R, Hernalsteens JP, Wyns L, Oscarson S, De Greve H, Hultgren S, Bouckaert J
PLoS One 3 e2040 (2008)
PMID: 18446213

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
Sequence domains:
Structure domain:

Structure analysis Details

Assembly composition:
homo tetramer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-140009 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecules (2 distinct):
Type 1 fimbrin D-mannose specific adhesin Chains: A, B
Molecule details ›
Chains: A, B
Length: 158 amino acids
Theoretical weight: 16.92 KDa
Source organism: Escherichia coli
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: P08191 (Residues: 22-179; Coverage: 57%)
Gene names: JW4283, b4320, fimH
Sequence domains: FimH, mannose binding
Structure domains: Fimbrial-type adhesion domain

Ligands and Environments

Carbohydrate polymer : NEW Components: NAG, MAN
Carbohydrate polymer
2 bound ligands:
Ligand NI 2 x NI
Ligand SO4 1 x SO4
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: EMBL/DESY, HAMBURG BEAMLINE X12
Spacegroup: P3121
Unit cell:
a: 90.562Å b: 90.562Å c: 79.48Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.187 0.184 0.241
Expression system: Escherichia coli BL21(DE3)

Quick links

Citations

41 review citations

Recent advances in understanding enteric pathogenic Escherichia coli.
Croxen et al. (2013)
40 more

14 mentions without citation

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
Mydock-McGrane et al. (2017)
13 more